Search results for "TMB"
showing 5 items of 5 documents
Peroksīdu noteikšana ar eksprestestu metodi
2017
Peroksīdu noteikšana ar eksprestestu metodi. Bruņeniece A., darba vadītājs Dr. ķīm. docents Ģībietis J. Bakalaura darbs, 44 lappuses, 10 tabulas, 26 attēli, 23 literatūras avoti. Latviešu valodā. Darbā apskatītas dažādas ūdeņraža peroksīda un peroksietiķskābes kvantitatīvās noteikšanas metodes. Veikta ITS firmas ekprestesta „Water-Works” teststrēmeļu kalibrēšana. Eksperimentāli izpētīta jonu spēka, pH un organiskā šķīdinātāja ietekme uz teststrēmeļu darbību. Iegūti kalibrēšanas grafiki un izveidotas krāsu standartskalas, izmantojot spektrofotometru – kolorimetru AvaMouse Avantes, kā arī izpētītа teststrēmeļu piеmērotība peroksīdu koncentrācijаs noteikšanаi atšķirīgās vidēs. Iegūtie rezultāt…
Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast canc…
2021
Different immunohistochemical programmed death-ligand 1 (PD-L1) assays and scorings have been reported to yield variable results in triple-negative breast cancer (TNBC). We compared the analytical concordance and reproducibility of four clinically relevant PD-L1 assays assessing immune cell (IC) score, tumor proportion score (TPS), and combined positive score (CPS) in TNBC. Primary TNBC resection specimens (n = 104) were stained for PD-L1 using VENTANA SP142, VENTANA SP263, DAKO 22C3, and DAKO 28–8. PD-L1 expression was scored according to guidelines on virtual whole slide images by four trained readers. The mean PD-L1 positivity at IC-score ≥1% and CPS ≥1 ranged between 53% and 75% with th…
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSC…
2020
Background The role of tumor mutational burden (TMB) is still debated for selecting advanced non-oncogene addicted non-small-cell lung cancer (NSCLC) patients who might benefit from immune checkpoint inhibitors (ICIs). Of note, TMB failed to predict a benefit in overall survival (OS) among such patients. Materials and methods The purpose of this meta-analysis was to compare efficacy outcomes among first-line immune-oncology (IO) agents versus standard platinum-based chemotherapy (CT) within two subgroups (TMB-low and TMB-high on either tissue or blood). We collected hazard ratios (HRs) to evaluate the association for progression-free survival (PFS) and OS, with the relative 95% confidence i…
Tumor mutational burden on cytological samples: A pilot study.
2020
Background Immune-checkpoint inhibitors (ICIs) represent an important treatment option for patients who have advanced stage non-small cell lung cancer (NSCLC). Currently, evaluation of the expression level of programmed death-ligand 1 (PD-L1) has proven highly successful as a positive predictive biomarker for ICIs. In addition to PD-L1, other promising predictive biomarkers are emerging, including high tumor mutational burden (TMB-H). However, measuring TMB-H remains challenging for several reasons, among which is the difficulty in obtaining adequate tissue material from NSCLC patients. There are no data in the current literature regarding the possibility of adopting cell blocks (CBs) for T…
Transmembrane BAX Inhibitor-1 Motif Containing Protein 5 (TMBIM5) Sustains Mitochondrial Structure, Shape, and Function by Impacting the Mitochondria…
2020
The Transmembrane Bax Inhibitor-1 motif (TMBIM)-containing protein family is evolutionarily conserved and has been implicated in cell death susceptibility. The only member with a mitochondrial localization is TMBIM5 (also known as GHITM or MICS1), which affects cristae organization and associates with the Parkinson&rsquo